文献速递哮喘

对「Dupilumab与哮喘患者淋巴瘤风险」队列研究的重大缺陷评论

Critical flaws in: "Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study".
PubMed 文献 · Eur Respir J · 2026-07-09

本文是对Ma等人关于Dupilumab治疗与哮喘患者淋巴瘤风险关联的队列研究的评论信。评论指出该研究存在关键方法学缺陷、生物学不合理性及发病风险聚焦问题三大关切,对结果解读提出质疑。

要点

  • 评论指出Ma等研究存在关键方法学缺陷,影响结果可靠性。
  • Dupilumab与淋巴瘤关联缺乏生物学合理性支持。
  • 研究对发病风险的聚焦方式存在问题,需谨慎解读结论。

核心结论

  • 评论认为Ma等的研究因方法学缺陷、生物学不合理性及发病风险聚焦问题,其得出的Dupilumab与淋巴瘤风险关联的结论值得质疑。

研究设计与样本

  • 本文为针对Ma等人基于人群的队列研究的评论信,原文研究设计与样本量未在评论中报告。

主要发现

  • 评论识别出原文存在三个主要关切领域:关键方法学缺陷、生物学不合理性、发病风险聚焦问题。

临床怎么用

  • 临床医生在解读Dupilumab与淋巴瘤风险关联的研究时,应关注其方法学局限性和生物学合理性,避免过度解读。

局限性

  • 评论未提供原文研究的具体样本量、效应值等数据,仅提出定性质疑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are three major areas of concern identified in the article on dupilumab treatment and lymphoma risk in patients with asthma by Ma and co-workers – crucial methodological flaws, biological implausibility, and incident risk of disease focus https://bit.ly/4a3nT2R We read with interest the article by Ma et al. [1], suggesting an association between dupilumab treatment and lymphoma risk in patients with asthma. With expanding prescribing of biologics, including dupilumab, for asthma, such findings are of consequence, necessitating in-depth assessment of data, methods and conclusions. We identified three major areas of concern regarding this article – crucial methodological flaws, biological implausibility, and incident risk of disease focus – that question the interpretation of the results.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bacharier LB, Busse WW, Jackson DJ, et al. Critical flaws in: "Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study". Eur Respir J. 2026. PMID: 42425748. doi:10.1183/13993003.01565-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。